摘要 |
The present application describes methods of treating obesity using DGAT-1 inhibitors according to Formula I: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R<SUP>1</SUP>, R<SUP>2</SUP>, R<SUP>3</SUP>, R<SUP>4 </SUP>and Z are described herein.
|